President and Chief Executive Officer
Mr. Radie is president, chief executive officer and a member of Zyla’s board of directors and has been since March 2012. Mr. Radie has had a successful career with more than three decades in the industry and has been responsible for the sale of five companies. In 2005 Mr. Radie led the sale of Vicuron Pharmaceuticals to Pfizer for $1.9 billion and most recently he was responsible for the sale of Topaz Pharmaceuticals Inc. to Sanofi Pasteur for an undisclosed amount. Mr. Radie served in senior management positions with a number of pharmaceutical and biotechnology companies, including Prestwick Pharmaceuticals, Inc., Morphotek, Inc., Vicuron Pharmaceuticals, Inc. and served as a director of Affinium Pharmaceuticals, Ltd. from July 2012 to March 2014, when a majority of Affinium’s assets were acquired by a third party. Mr. Radie began his career in the life sciences at Eli Lilly and Company where he worked for 18 years in sales and marketing positions with increasing levels of responsibility. Mr. Radie serves on the board of Paratek Pharmaceuticals, a biopharmaceutical company, Pennsylvania Bio, an industry group supporting Pennsylvania life sciences companies, Veloxis, a public commercial-stage company, and Horse Power for Life, a non-profit organization dedicated to improving the quality of life for individuals diagnosed with cancer. Mr. Radie received his B.S. in chemistry from Boston College.
Mark Strobeck, Ph.D.
Executive Vice President and Chief Operating Officer
Dr. Strobeck is executive vice president and chief operating officer, a position he’s held since October 2015. He joined Zyla in February 2014 as chief business officer (CBO). Previously Dr. Strobeck was president and chief executive officer of Corridor Pharmaceuticals which he successfully sold to AstraZeneca and chief business officer of Topaz Pharmaceuticals which he sold to Sanofi Pasteur. Dr. Strobeck was chief business officer at Trevena Inc., and vice president of business development at GlaxoSmithKline. Before working at these healthcare companies, Dr. Strobeck was a venture capitalist at SR One Ltd., the wholly owned venture capital arm of GSK and Euclid SR Partners.
Dr. Strobeck earned a Ph.D. in pharmacology and cell biophysics from the University of Cincinnati, completed a post-doctoral fellowship in cardiovascular medicine at the University of Pennsylvania and received his bachelor’s degree from St. Lawrence University.
H. Jeffrey Wilkins M.D.
Senior Vice President, Chief Medical Officer
Dr. Wilkins joined Zyla in June 2019 and serves as senior vice president, chief medical officer (CMO). Prior to joining Zyla, he served as CMO at Lycera, a biopharmaceutical company developing treatments for autoimmune diseases and cancers. Prior to that role, Dr. Wilkins served as clinical lead and partner at Nexeption Therapeutics which works to bring together product opportunities, management teams and funding. Before his time at Nexeption, he also was CMO and head of medical affairs at Ceptaris Therapeutics which was purchased by Actelion. Prior to those positions,
Dr. Wilkins held senior level positions at Cephalon and GlaxoSmithKline.
Before working in life sciences companies, he was in clinical practice for about a decade. He founded and was CEO of TriValley Primary Care, a 27-physician and seven-site primary care group. Dr. Wilkins has authored numerous scientific publications. He received his bachelor’s degree from Bucknell University and his medical degree from Temple University where he also did his internship and residency.
E. Blair Clark-Schoeb
Senior Vice President, Communications
Ms. Clark-Schoeb, senior vice president, communications, leads our investor relations, public relations, advocacy relations and government affairs work. She has two decades of experience helping healthcare companies develop unique and effective communications programs. Prior to joining Zyla in February 2015, Ms. Clark-Schoeb led her own consulting business, working with pharmaceutical and biotechnology companies such as Sanofi, Syndax, Horizon Pharmaceuticals and Topaz Pharmaceuticals. Prior to that she was senior associate at W2O, director of investor relations at Burns McClellan, director of corporate finance at The Medicines Company and a healthcare investment banker at Donaldson, Lufkin and Jenrette. Ms. Clark-Schoeb received her bachelor’s degree from Harvard University.
Senior Vice President, General Counsel and Secretary
Ms. Timmins has been with Zyla since April 2016 and currently serves as senior vice president, general counsel and secretary. Prior to joining Zyla, Ms. Timmins served in positions of increasing responsibility at Aramark, a food service, facilities, and uniform services provider to clients in fields including education, healthcare, business, corrections and leisure, for more than 12 years. Her most recent position at Aramark was vice president, associate general counsel and assistant secretary. Ms. Timmins received her B.A. in Government and Economics from the University of Notre Dame and her J.D. from the William and Mary School of Law.
Executive Director of Human Resources
Ms. Biancarelli has been the executive director of human resources since April 2019. She is responsible for leading the human resources (HR) team and functions at Zyla including policies and procedures, compensation and benefits, employee relations, talent management and organizational development. Ms. Biancarelli has over 25 years of experience in the pharmaceutical and life sciences field bringing insight and skills that contribute to a company’s growth, strategy and culture. Most of her experience has been as a lead business partner for commercial operations in both start up and mid-size companies. Prior to joining Zyla, she served in leadership positions at both development-stage and commercial-stage organizations. Ms. Biancarelli held various HR positions at Bio-Pharm Clinical Services, Auxilium Pharmaceuticals and Recro Pharma. Ms. Biancarelli received her bachelor’s degree from Pennsylvania State University.